NanoString Expects Q2 Sales Of Over $44M, Up Approximately 37% Y/Y, Above Upper End Of The Company's Guidance Of $40M-$42M, Consensus Of $41M
Portfolio Pulse from Benzinga Newsdesk
NanoString (NSTG) expects Q2 sales to exceed $44M, a 37% increase YoY, surpassing the company's guidance of $40M-$42M and consensus of $41M. Spatial biology revenue is expected to be over $23M, in line with consensus, while nCounter revenue is expected to be around $21M, above the guidance range of $17M-$18M and consensus of $18M.
July 10, 2023 | 9:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NanoString's Q2 sales and revenues are expected to exceed both the company's guidance and consensus estimates, indicating strong performance.
The news indicates that NanoString is expected to outperform its own guidance and consensus estimates for Q2 sales and revenues. This suggests strong performance and could positively impact investor sentiment, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100